Could What We Eat Influence Immunotherapy Side Effects? A New Study Makes the Question Harder to Ignore

By Dr Chef Chuck Hayworth | Real Medical Meals™

Cancer treatment asks an enormous amount of a person. When a therapy is helping, the possibility of stopping because of severe side effects can be devastating.

As a cancer survivor and chef, that is what caught my attention about new research from the University of Pittsburgh.

Published October 22, 2026, in Cell, the study investigates how diet, gut microbes, and immune regulation interact during immune checkpoint inhibitor treatment. Its findings raise an important possibility: the nutritional environment surrounding treatment may influence the body’s susceptibility to harmful inflammation.

That possibility deserves attention. It also deserves careful explanation.

What the researchers actually found

In the study by Patra and colleagues⁠, researchers developed a mouse model called LISA—lifestyle-induced susceptibility to immune-related adverse events.

Mice received either regular chow or a formulated Western-style diet, low in fiber and high in fat and processed carbohydrates, beginning 14 days before anti-PD-1 treatment.

The Western-diet group developed inflammation affecting multiple organs, including the colon, liver, skin, and lungs. Researchers also identified changes in gut microbes and immune cells. (sciencedirect.com⁠)

This was not a trial assigning cancer patients to different menus. The dietary intervention evidence came from animals.

The immune system needs restraint as well as strength

Immune checkpoint inhibitors release restraints that can prevent immune cells from attacking cancer. Those same treatments can also trigger inflammation in healthy organs.

Regulatory T cells help keep excessive immune responses under control. In this research, some became “fragile”: they retained their identity but lost important aspects of their protective function.

The investigators also observed related immune-cell abnormalities in patients with immunotherapy-associated colitis. That provides a human connection to the animal findings, although it does not prove that those patients’ diets caused their complications. (pubmed.ncbi.nlm.nih.gov⁠)

For me, the practical lesson is that “boosting immunity” is an inadequate description of what people undergoing cancer treatment need. Supporting someone through treatment requires attention to regulation, nourishment, and tolerance.

Why the microbiome experiments matter

According to the University of Pittsburgh’s research account⁠, transferring gut microbes from human donors with different dietary patterns into germ-free mice changed the recipients’ susceptibility to inflammation.

The study abstract adds an important detail: the recipient mice’s diet interacted with the transferred microbes to shape susceptibility.

That strengthens the argument that microbes participate in the process. It also suggests that a microbiome cannot be understood independently of what its host eats. (immunology.pitt.edu⁠, pubmed.ncbi.nlm.nih.gov⁠)

My interpretation is that future nutritional care may need to consider the relationship between food and microbial function, rather than simply labeling individual bacteria “good” or “bad.”

Some of the changes could be reversed—in mice

The UPMC research announcement⁠ reports that changing the animals’ diet, providing selected metabolites, or targeting inflammatory signaling in regulatory T cells reduced adverse-event severity.

The university’s departmental account also reports that a targeted regulatory-T-cell intervention improved inflammation without compromising tumor control in the mouse experiments. (upmc.com⁠, immunology.pitt.edu⁠)

That is a promising research direction. Preserving cancer control while reducing harm is exactly the outcome patients need.

However, these findings do not establish a human supplement regimen, a fiber prescription, or a proven nutritional treatment for immunotherapy toxicity.

What makes this research strong—and where it falls short

Its strength is the combination of approaches: controlled animal experiments, microbiome transfers, immune-cell interventions, and comparisons with patient samples. Those methods help researchers examine a biological mechanism rather than merely report that two things occur together. (sciencedirect.com⁠, upmc.com⁠)

Several limits matter when interpreting the results:

Animal results require human testing. A successful intervention in mice does not establish clinical benefit or safety in patients.
The diet changed several things together. Comparing a low-fiber, high-fat formulated diet with regular chow cannot, by itself, isolate one responsible ingredient.
The patient findings do not establish dietary causation. They support relevance to human disease, but they are not a randomized nutrition trial.
“Lifestyle” has a specific meaning here. The authors use it for the dietary, metabolic, and microbial environment; this was not a comprehensive test of sleep, stress, exercise, and other habits. (sciencedirect.com⁠)
The study supports further investigation. It does not justify blaming a patient’s food choices for a treatment complication.

Earlier human research supports the broader question

A separate 2021 study published in ⁠Science⁠ examined dietary fiber and immunotherapy outcomes in 128 patients with melanoma.

Higher reported fiber intake was associated with longer progression-free survival, with the strongest association among patients reporting sufficient fiber and no probiotic use.

That human evidence was observational. It concerned treatment outcomes, and it did not prove that fiber prevents immune-related colitis. Still, it helps explain why researchers are taking the diet–microbiome–immunotherapy relationship seriously. (pmc.ncbi.nlm.nih.gov⁠)

The advice patients should not take from this headline

Do not respond to diarrhea during immunotherapy by suddenly adding large amounts of fiber.

The National Cancer Institute⁠ explains that diarrhea can result from immunotherapy-related colitis and should be reported to the healthcare team. During diarrhea, clinicians may recommend temporarily reducing fiber and adjusting food and fluid intake.

New or worsening diarrhea, abdominal pain, or black or bloody stools warrants prompt contact with the oncology team. Severe symptoms require urgent assessment. (cancer.gov⁠, cancer.gov⁠)

The meal that suits a person before treatment may need substantial changes during an inflammatory complication.

Likewise, “microbiome support” is not a reason to start probiotics, fiber supplements, or experimental metabolites independently. Discuss supplements with the treatment team.

Food supports care. Immune-related inflammation may require medical treatment, including corticosteroids or other therapies selected by the oncology team. (cancer.gov⁠, cancer.gov⁠)

What this means for Real Medical Meals™

My takeaway is that meal support should be responsive to the person’s treatment, symptoms, and clinical guidance.

What we eat can influence our risk of certain cancers. Chronic inflammation is one biological pathway that may connect dietary patterns with cancer development, alongside metabolic, hormonal, and other mechanisms. This new immunotherapy study strengthens the case for investigating the diet–microbiome–immune relationship, but it does not establish that a Western diet causes cancer through the mechanism identified here.

For Real Medical Meals™, that means translating the healthcare team’s recommendations into food someone can realistically eat:

Preparing smaller portions when appetite is limited.
Adjusting textures, fiber sources, and ingredients as tolerance changes.
Building meals around prescribed protein, energy, and fluid needs.
Updating menus when the oncology team changes recommendations.
Giving caregivers practical preparation and reheating instructions.
A recommendation has limited value if a patient is too exhausted to shop, too nauseated to cook, or unsure how to prepare it.

Our role is to help close that practical gap. We should not claim that our meals prevent immunotherapy complications; this study has not demonstrated that.

Within CL5 Longevity Cuisine, the findings are especially relevant to Gut Intelligence. They also reinforce my view that a nutrition framework must remain flexible enough to meet the needs of someone in active treatment.

A personal reason to keep asking better questions

My own cancer experience is part of why I take this work seriously. It does not give me the answer to what every patient should eat. It gives me a reason to keep asking how we can make nourishment more practical, more personal, and better connected to care.

This research brings an important question into sharper focus:

Could carefully designed nutritional support eventually help some patients tolerate immunotherapy more safely?

We do not have that clinical answer yet. We have a stronger reason to investigate it—and a responsibility to communicate the evidence honestly.

Real Medical Meals™ provides individualized culinary support informed by the recommendations of a client’s healthcare team. Nutrition changes during cancer treatment should be coordinated with the treating clinicians and an oncology registered dietitian.